Table 1 Clinical and biochemical characteristics of included patients
From: Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation
T1DM (n = 46) | LADA (n = 46) | p | |
|---|---|---|---|
Females, n (%) | 23 (50.0%) | 24 (52.2%) | 0.835 |
Age at diabetes diagnosis, median (IQR) | 38 (15) | 42 (15) | 0.057 |
Months between diagnosis of diabetes and insulin therapy beginning, median (IQR) | 0 (0.0) | 48 (56.3) | < 0.001* |
Months between diagnosis of diabetes and diagnosis of autoimmune aetiology, median (IQR) | 0 (3.0) | 60 (92.3) | < 0.001* |
Diabetes duration at the last follow-up, years, median (IQR) | 8.0 (7.5) | 11.0 (10.5) | 0.023* |
At the diagnosis of diabetes | |||
Symptoms at presentation, n (%) | 40 (87.0%) | 21 (45.7%) | < 0.001** |
Diabetic ketoacidosis, n | 2 | 0 | |
Polyuric/polydipsic syndrome, n | 38 | 21 | |
At the measurement of diabetes-related autoantibodies | |||
BMI (kg/m2), mean (± SD) | 24.1 (± 3.8) | 26.1 (± 5.2) | 0.042*** |
A1C (%), mean (± SD) | 10.3 (± 2.4) | 9.5 (± 2.2) | 0.113 |
C-peptide (ng/mL), median (IQR) | 0.7 (0.6) | 1.0 (1.4) | 0.152 |
Number of positive antibodies, median (IQR) | 2 (2.0) | 1 (1.0) | 0.013* |
Patients with > 1 positive antibody, n (%) | 31 (67.4%) | 19 (41.3%) | 0.012** |
Positive GADA, n/total (%) | 43/46 (93.5%) | 39/46 (84.8%) | 0.180 |
GADA title of patients with positive GADA (U/mL), median (IQR) | 21.4 (94.1) | 11.9 (60.4) | 0.229 |
Positive ICA, n/total (%) | 30/43 (69.8%) | 23/38 (60.5%) | 0.383 |
Positive IA2, n/total (%) | 17/43 (39.5%) | 10/45 (22.2%) | 0.078 |
IA2 title of patients with positive IA2 (U/mL), median (IQR) | 10.5 (31.1) | 4.1 (10.8) | 0.093 |
Positive IAA, n/total (%) | 4/38 (10.5%) | 1/35 (2.9%) | 0.359 |